
A $100-million investment will expand a range of the CDMO’s service capabilities and offerings.

A $100-million investment will expand a range of the CDMO’s service capabilities and offerings.

SGS announces expansion of cell bank and bulk harvest testing services.

Fluorescence has long been used to detect biological targets. As these measurements are becoming more and more quantitative, standards are needed to ensure accuracy and reproducibility.

The investment in the company’s Mississauga, Canada, laboratory includes an expansion of existing cell/tissue culture capabilities, flow cytometry, mass spectrometry facilities, and more.

The contract development and manufacturing organization expanded its analytical chemistry suite and added a new office in Boston, MA.

The pharmaceutical, clinical, and bioanalytical contract solutions provider has implemented advanced techniques for the collection and use of peripheral blood mononuclear cells (PBMCs) for early-phase clinical trials at its Clinical Pharmacology Unit in Antwerp, Belgium.

An expansion of laboratory facilities in Geneva, Switzerland expands SGS services for high-order structure analysis.

The API and drug product provider will invest £375,000 (US$493,000) in additional nuclear magnetic resonance (NMR) instrumentation at its headquarters in Craigavon, UK.

The contract service provider will invest in a laboratory expansion at its site located in Tredegar, Wales, UK.

Access to multiple analytical techniques is essential for fully characterizing complex protein formulations.

The contract research organization has added a new analytical laboratory in Middleton, WI, to expand its biologics testing capacity.

The new 73,000-square-foot facility is one of several expansions to support the company’s biologics testing capabilities.

Contract testing organizations can provide bio/pharma companies with a cost-effective way to adapt to new technologies and regulations.

A review of the latest investments in facilities, equipment, and acquisitions by biopharma contract service providers.

The company aims to add the additional analytical services in the European Union throughout 2018.

A $800-million acquisition of MPI Research expands Charles River's offerings for early-stage contract research.

KBI Biopharma's acquisition of Elion Labs expands KBI's biophysical and analytical characterization capabilities.

The acquisition strengthens Charles River Laboratories’ capabilities in the oncology and immunology therapeutic areas.

Almac Group will acquire BioClin Laboratories to expand Almac’s analytical service offerings.

The collaboration will focus on developing a novel and differentiated challenge model for respiratory syncytial virus.

Detecting viral contaminants in biologic-based medicines-and identifying their source-requires a holistic testing approach.

The Bridgewater facility will provide a range of contract services for biopharmaceutical and pharmaceutical manufacturers, and also serve electronics chemicals suppliers.

Alcami will move its headquarters to Durham, NC while maintaining its manufacturing and laboratory operations in Wilmington, NC.

Catalent expands the scope of the OptiForm Solution Suite to bridge gap from late-stage discovery to Phase I trials.

IDBS described benefits and best practices for laboratory electronic data systems.